A multi-institutional research team has identified a new mechanism by which the dangerous brain tumors called gliomas develop resistance to anti-angiogenic treatment. The team’s report, published online in Cancer Cell, describes finding how different molecular subtypes of glioma cells use different strategies to spread through the brain and how anti-angiogenic treatment selects for a treatment-resistant cellular subtype.
“Despite massive basic and clinical research efforts, the treatment of glioblastoma and other malignant gliomas remains one of the most challenging tasks in clinical oncology,” says Rakesh Jain, PhD, director of the Edwin L. Steele Laboratories for Tumor Biology in the Massachusetts General Hospital (MGH) Department of Radiation Oncology and co-senior author of the report. “Glioblastomas are highly vascularized and interact closely with pre-existing blood vessels for oxygen and nutrients. They also contain a very diverse population of cells, with characteristics of stem cell and other cells found within the brain, and may use different strategies to recruit or access blood vessels, depending on the local microenvironment and on treatments that are applied.”
Previous studies have revealed several ways that gliomas can migrate within the brain – including “co-option” in which single cells migrate along blood vessels or as dense clusters that lead to the formation of new blood vessels. To investigate mechanisms underlying these two strategies, the research team, primarily comprised of investigators from MGH and the University of California San Francisco (USCF), focused on a protein called Olig2, normally involved in the development of brain cells called oligodendrocytes and expressed in most glioma subtypes.
Oligodendrocyte precursors (OPCs) that express Olig2 can act as glioma progenitors; and within OPCs, signaling controlled by a protein called Wnt7 is known to play a role in embryonic vascular development within the brain, including the cells’ migration along blood vessels. The team’s series of experiments revealed the following:
- Olig2-positive glioma cells invade brain tissue by single-cell co-option without affecting the existing vasculature. Increased Wnt7 expression within those cells was required for that strategy.
- Olig2-negative cells grow as clusters around blood vessels – which show increased size and density – and express high levels of the angiogenic factor VEGF. Olig2-negative gliomas exhibit a breakdown in the blood brain barrier and increased activation of innate immune cells, leading to neuroinflammation.
- In a mouse model of Olig2-positive gliomas that express Wnt7, treatment with drugs that inhibit Wnt or another protein in the Wnt pathway induced glioma cells to lose contact with blood vessels and form the sort of clusters usually seen in Olig2-negative gliomas.
- In mice implanted with Olig2-positive, Wnt7-expressing cells from human gliomas, treatment of late-stage tumors with a Wnt inhibitor and the chemotherapy drug temozolomide improved survival compared with temozolomide alone.
- Treatment of glioma cell lines with the VEGF inhibitor bevacizumab promoted single-cell, vascular co-option, most likely by increasing Olig2 expression. Analysis of bevacizumab-resistant cells – including paired samples from human patients taken before and after bevacizumab treatment – supported the conclusion is that anti-VEGF treatment selected for the Olig2-positive, Wnt-expressing cells that use that vascular strategy.
“We have discovered how Wnt signaling drives the process of single-cell, vascular co-option in gliomas, a mechanism that is strongly induced by anti-angiogenic treatment,” says Jain, the Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School.
Co-senior author David Rowich, MD, PhD, ScD, of UCSF and the University of Cambridge in the U.K., adds, “These findings have significant therapeutic implications for our understanding of heterogeneity in glioma and how tumor components exploit alternative strategies to interact successfully with the vasculature despite anti-angiogenic treatment. Our identification of the Olig2/Wnt7 vessel co-option pathway reveals a potential target for future combination therapies.” The co-lead authors are
Amelie Griveau, PhD, UCSF, and Giorgio Seano, PhD, Steele Labs, MGH Radiation Oncology. Support for the study includes SPORE grants P50 CA097257 and P50 CA165962, and grants R35 CA197743 and P01 CA080124 from the National Cancer Institute; grants from the Bryan’s Dream Foundation, Pediatric Brain Tumor Foundation, Loglio Foundation, Howard Hughes Medical Institute, the Wellcome Trust, the National Foundation for Cancer Research and the Harvard Ludwig Cancer Center.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service and returned to the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."
Media contact: Katie Marquedant, email@example.com, 617 726-0337